Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease

Blood

Volumn 95, Issue 5, 2000, Pages 1517-1532

  Lane, David A ^a   Grant, Peter J ^b  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING INHIBITOR; FIBRINOGEN RECEPTOR; FIBRINOLYTIC FACTOR; GLYCOPROTEIN IB; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR;

DNA POLYMORPHISM; ENDOTHELIUM; ENVIRONMENTAL FACTOR; FIBRINOLYSIS; GENE DELETION; GENE MUTATION; HEMOSTASIS; HEREDITY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE; THROMBOEMBOLISM; THROMBOSIS; THROMBUS;

EID: 0034161456     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.5.1517.005k48_1517_1532     Document Type: Review

References (226)

1. Egeberg O. Inherited antithrombin III deficiency causing thrombophilia. Thromb Diath Haemorrh. 1965;13:516.
2. Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest. 1981;68:1370.
3. Comp PC, Nixon RR, Cooper MR, Esmon CT. Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest. 1984;74:2082.
4. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993;90:1004.
5. Dahlback B. Inherited resistance to activated protein C, a major cause of venous thrombosis, is due to a mutation in the factor V gene. Haemostasis. 1994;24:139.
6. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64.
7. Voorberg J, Roelse J, Koopman R, et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet. 1994;343:1535.
8. Majerus PW. Human genetics: bad blood by mutation. Nature. 1994;369:14.
9. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia, part 1. Thromb Haemost. 1996;76:651.
10. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet. 1999;353:1167.
11. Martinelli I, Mannucci PM, de Stefano V, et al. Different risks of thrombosis in four coagulantion defects associated with inherited thrombophilia: a study of 150 families. Blood. 1998;92:2353.
12. Kalafatis M, Mann KG. Factor V Leiden and thrombophilia. Arterioscler Thromb Vasc Biol. 1997;17:620.
13. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem. 1994;269:31,869.
14. Nicolaes GAF, Tans G, Thomassen MCLGD, et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor Va R506Q by activated protein C. J Biol Chem. 1995;270:21,158.
15. Rosing J, Hoekema L, Nicolaes GAF, et al. Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor Va R506Q by activated protein C. J Biol Chem. 1995;270:27,852.
16. Shen L, Dahlback B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor Villa. J Biol Chem. 1994;269:18,735.
17. Thorelli E, Kaufman RJ, Dahlback B. The C-terminal region of the factor V B-domain is crucial for the anticoagulant activity of factor V. J Biol Chem. 1998;273:16,140.
18. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 1993;342:1503.
19. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction. N Engl J Med. 1995;332:912.
20. Zivelin A, Griffin JH, Xu X, et al. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood. 1997;89:397.
21. Koeleman BP, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood. 1994;84:1031.
22. Zoller B, Berntsdotter A, Garcia de Frutos P, Dahlback B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood. 1995;85:3518.
23. van Boven HH, Reitsma PH, Rosendaal FR, et al. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost. 1996;75:417.
24. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344:1453.
25. Rosing J, Tans G, Nicolaes GAF, et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol. 1997;97:233.
26. Martinelli I, Landi G, Merati G, Cella R, Tosetta A, Mannucci PM. Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb Haemost. 1996;75:393.
27. Ryan DH, Crowther MA, Ginsberg JS, Francis CW. Relation of factor V Leiden genotype to risk for acute deep venous thrombosis after joint replacement surgery. Ann Intern Med. 1998;128:270.
28. Desmarais S, de Moerloose P, Reber G, Minazio P, Perrier A, Bounameaux H. Resistance to activated protein C in an unselected population of patients with pulmonary embolism. Lancet. 1996;347:1374.
29. Rintelen C, Pabinger I, Knobl P, Lechner K, Mannhalter C. Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost. 1996;75:229.
30. Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Undpaintner K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation. 1995;92:2800.
31. Simioni S, Prandoni P, Lensing AWA, et al. The risk of recurrent venous thromboembolism in patients with an Arg506 to Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med. 1997;336:399.
32. Eichinger S, Pabinger I, Stumpflen A, et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost. 1997;77:624.
33. De Stefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and G20210A prothrombin mutation. N Engl J Med. 1999;341:801
34. Chan WP, Lee CK, Kwong YL, Lam CK, Liang R. A novel mutation of factor V in Hong Kong Chinese. Blood. 1998;91:1135.
35. Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: a new mutation (Arg306 to Thr) associated with resistance to activated protein C. Blood. 1998;91:1140.
36. de Visser MCH, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood. 1999;93:1271.
37. Bernardi F, Faioni EM, Castoldi E, Castaman G, Sacchi E, Mannucci PM. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood. 1997;90:1552.
38. Alhenc-Gelas M, Nicaud V, Gandrille S, et al. The factor V gene A4070G mutation and the risk of venous thrombosis. Thromb Haemost. 1999;81:193.
39. Faioni EM, Franchi F, Bucciarelli P, et al. Coinheritance of the HR2 haplotype in the factor V gene confers an increased risk of venous thrombosis to carriers of factor V R506Q (factor V Leiden). Blood. 1999;94:3062.
40. Castoldi E, Rosing J, Lunghi B, et al. Factor V gene mutations (r2 gene) are associated with coronary artery disease in elderly people [abstract]. Thromb Haemost. 1999;509.
41. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698.
42. Rosendaal FR, Doggen CJM, Zivelin A, et al. Geographic distribution of the prothrombin 20210 G to A prothrombin variant. Thromb Haemost. 1998;79:706.
43. Ferraresi P, Marchetti G, Legnani C, et al. The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombophilias and is not increased in frequency in arterial disease. Arterioscler Thromb Vasc Biol. 1997;17:2418.
44. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med. 1998;338:1793.
45. Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation. 1999;99:999.
46. Zivelin A, Rosenberg N, Faier S, et al. A single genetic origin for the common prothrombotic G20210A polymorphism in the prothrombin gene. Blood. 1998;92:1119.
47. Eichinger S, Minar E, Hirschl M, et al. The risk of early recurrent venous thrombosis after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost. 1999;81:14.
48. rd ed. Edinburgh: Churchill Livingstone; 1994;531.
49. Tuddenham EGD, Cooper DN. The Molecular Genetics of Haemostasis and Its Inherited Disorders. Oxford: Oxford University Press; 1994
50. Anwar R, Gallivan L, Edmonds SD, Markham AF. Genotype/phenotype correlations for coagulation factor XIII: specific normal polymorphisms are associated with high or low factor XIII specific activity. Blood. 1999;93:897.
51. Suzuki K, Iwata M, Ito S, Matsui K, Uchida A, Mizoi Y. Molecular basis for subtype differences of the "a" subunit of coagulation factor XIII with description of the genesis of the subtypes. Hum Genet. 1994;94:129.
52. Anwar R, Stewart AD, Miloszewski KJA, Losowsky MS. Molecular basis of inherited factor XIII deficiency: identification of multiple mutations provides insights into protein function. Br J Haematol. 1995;91:728.
53. Mikkola H, Syrjala M, Rasi V, et al. Deficiency in the A-subunit of coagulation factor XIII: two novel point mutations demonstrate different effects on transcript levels. Blood. 1994;84:517.
54. Suzuki K, Henke J, Iwata M, et al. Novel polymorphisms and haplotypes in the human coagulation factor XIII A-subunit gene. Hum Genet. 1996;98:393.
55. Kamura T, Okamura T, Murakawa M, et al. Deficiency of coagulation factor XIIIa subunit caused by dinucleotide deletion at the 5'-end of exon 3. J Clin Invest. 1992;90:315.
56. Catto AJ, Kohler HP, Coore J, Mansfield MW, Stickland MH, Grant PJ: Association of a common polymorphism in the factor XIII gene with venous thrombosis. Blood. 1999;93:906.
57. Franco RF, Reitsma PH, Lourenco D, et al. Factor XIII Val34Leu is a genetic factor involved in the aetiology of venous thrombosis. Thromb Haemost. 1999;81:676.
58. Kangsadalampai S, Board PG. The Val34Leu polymorphism in the A subunit of coagulation Factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity. Blood. 1998;92:2766.
59. Kohler HP, Ariens RAS, Whitaker P, Grant PJ. A common coding polymorphism in the Factor XIII A-subunit gene (FXIIIVal34Leu) affects cross linking activity. Thromb Haemost. 1998;80:704, 1998
60. Bangalore N, Drohan WN, Orthner CL High affinity binding sites for activated protein C and protein C on cultured human umbilical vein endothelial cells independent of protein S and distinct from known ligands. Thromb Haemost. 1994;72:465.
61. Fukudome K, Esmon CT. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem. 1994;269:26,486.
62. Fukudome K, Kurosawa S, Sterns-Kurosawa DJ, He X, Rezaie AR, Esmon CT. The endothelial cell protein C receptor: cell surface expression and direct ligand binding by the soluble receptor. J Biol Chem. 1996;271:17,491.
63. Sterns-Kurosawa DJ, Kurosawa S. Mollica JS, Ferrell GL, Esmon CT. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci USA. 1996;93:10,212.
64. Lazik Z, Mitro A, Tatlor FBJ, Ferrel G, Esmon CT. Human protein C receptor is primarily present on endothelium of large blood vessels: implications for the control of the protein C pathway. Circulation. 1997;96:3633.
65. Simmonds RE, Lane DA. Structural and functional implications of the intron/exon organization of the human endothelial cell protein C/activation protein C receptor (EPCR) gene: comparison with the structure of CD1/major histocompatibility complex a1 and a2 domains. Blood. 1999;94:632.
66. Merati G, Biguzzi F, Oganesyan N, et al. A23bp insertion in the endothelial protein C receptor (EPCR) gene in patients with myocardial infarction and deep vein thrombosis [abstract]. Thromb Haemost. 1999;507
67. Ohlin A-K, Marlar RA. The first mutation identified in the thrombomodulin gene in a 45 year old man presenting with thromboembolic disease. Blood. 1995;85:330.
68. Ohlin A-K, Marlar RA. Mutations in the thrombomodulin gene associated with thromboembolic disease. Thromb Haemost. 1995;73:1096.
69. Ohlin AK, Norlund L, Marlar RA. Thrombomodulin gene variations and thromboembolic disease. Thromb Haemost. 1997;78:396.
70. van der Velden PA, Krommenhoek-Van Es T, Allaart CF, Bertina RM, Reitsma PH. A frequent thrombomodulin amino acid diamorphism is not associated with thrombophilia Thromb Haemost. 1991;65:511.
71. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep vein thrombosis. Lancet. 1995;345:152.
72. O'Donnell J, Tuddenham EGD, Manning R, Kemball-Cooke G, Johnson D, Laffan M. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to acute phase reaction. Thromb Haemost. 1997;77:825.
73. Mansvelt EPG, Laffan M, McVey JH, Tuddenham EGD. Analysis of the F8 gene in individuals with high plasma factor VIII:C levels and associated venous thrombosis. Thromb Haemost. 1998;80: 561.
74. Kamphuisen PW, Houwing-Duistermaat JJ, van Houwelingen HC, Eikenboom JCJ, Bertina RM, Rosendaal FR. Familial clustering of factor VIII and von Willebrand factor levels. Thromb Haemost. 1998;79:323.
75. Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost. 1999;81:165.
76. Cattaneo M, Tsai MY, Bucciarelli P, et al. A common mutation in the methylenetetrahydrofolate reductase gene (C677T) increases the risk for deep vein thrombosis in patients with mutant factor V (factor V:Q506). Arterioscler Thromb Vasc Biol. 1997;17:1662.
77. den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep vein thrombosis. N Engl J Med. 1996;334:759.
78. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia. 1991;34:457.
79. Juhan-Vague I, Thompson SG, Jespersen J, on behalf of the ECAT Angina Pectoris Study Group I. Involvement of the hemostatic system in the insulin resistance syndrome: a study of 1,500 patients with angina pectoris. Arterioscler Thromb 1993;13:1865.
80. Mansfield MW, Stickland MH, Grant PJ. Circulating levels of factor VII, fibrinogen and von Willebrand factor and features of insulin resistance in first degree relatives of patients with NIDDM. Circulation. 1996;94:2171.
81. Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986;2:533.
82. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311: 501-505.
83. Jansson JK, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J. 1991;66:351.
84. Hamsten A, De Faire U, Walldius G, et al. Plasminogen activatory inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;ii:3.
85. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet. 1994;343:940.
86. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and Factor VII in the prediction of coronary risk. Arterioscler Thromb. 1994;14:54.
87. Lee AJ, Lowe GDO, Woodward M, Tunstall Pedoe H. Fibrinogen in relation to a personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease and family history: the Scottish Heart Health Study. Br Heart J. 1993;69:338.
88. Meade TW, Imeson J, Stirling Y. Effects of changes in smoking and other characteristics on clotting factors and the risk of ischaemic heart disease. Lancet. 1987;ii:986.
89. Kant JA, Furnace AJ, Saxe D, Simon MI, McBride OW, Crabtree GR. Evolution and organization of the fibrinogen locus on chromosome 4: gene duplication accompanied by transcription and inversion. Proc Natl Acad Sci U S A. 1985;82:2344.
90. Courtois G, Morgan JG, Campbell LA, Fourel G, Crabtree GR. Interaction of a liver specific nuclear factor with the fibrinogen and a-1 antitrypsin promoters. Science. 1987;238:688.
91. Dalmon J, Laurent M, Courtois G. The human b-fibrinogen promoter contains hepatocyte nuclear factor 1-dependent interleukin-6-responsive element. Mol Cell Biol. 1993;13:1183.
92. Humphries SE, Cook M, Dubowitz M, Stirling Y, Meade TW. Role of genetic variation at the fibrinogen locus in determination of fibrinogen concentrations. Lancet. 1987;i:1452.
93. Humphries SE, Green FR, Temple A, et al. Genetic factors determining thrombosis and fibrinolysis. Ann Epidemiol. 1992;2:371.
94. Yu S, Sher B, Kudryk B, Redman CM. Intracellular assembly of human fibrinogen. J Biol Chem. 1984;259:10,574.
95. Hamsten A, Iselius L, De Faire U, Blomback M. Genetic and cultural inheritance of plasma fibrinogen concentrations. Lancet. 1987;2:988.
96. Friedlander Y, Elkana Y, Sinnreich R, Kark JD. Genetic and environmental sources of fibrinogen variability in Israeli families: The Kibbutzim Study. Am J Hum Genet. 1995;56:1194.
97. Behague I, Poirier O, Nicaud V, et al. b fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. Circulation. 1996;93:440.
98. -455-A b-gene) is associated with differences in plasma fibrinogen levels in young men and women from different regions in Europe: evidence for gender-genotype-environment interaction. Arterioscler Thromb Vasc Biol. 1995;15:96.
99. -455-A) in the b-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease: a study of 9,127 individuals based on the Copenhagen City Heart Study. J Clin Invest. 1997;99:3034.
100. Gardemann A, Schwartz O, Haberbosch W, et al. Positive association of the b fibrinogen H1/H2 gene variation to basal fibrinogen levels and to increase in fibrinogen concentration during acute phase reaction but not to coronary artery disease and myocardial infarction. Thromb Haemost. 1997;77:1120.
101. de Maat MPM, Kastelein JJP, Jukema JW, et al. -455G/A polymorphism of the b-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute phase reaction pattern of fibrinogen. Arterioscler Thromb Vasc Biol. 1998;18:265.
102. Carter AM, Mansfield MW, Stickland MH, Grant PJ. b-fibrinogen gene -455 G/A polymorphism and fibrinogen levels: risk factors for coronary artery disease in subjects with NIDDM. Diabetes Care. 1996;19:1265.
103. Zito F, Di Castelnuovo A, Amore C, D'Orazio A, Donati MB, lacoviello L. Bcl I polymorphism in the fibrinogen b-chain gene is associated with the risk of familial myocardial infarction by increasing plasma fibrinogen levels: a case-control study in a sample of GISSI-2 patients. Arterioscler Thromb Vasc Biol. 1997;17:3489.
104. 148 to T) is associated with carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 1998;18:487.
105. Carter AM, Catto AJ, Bamford JM, Grant PJ. Gender-specific associations of the fibrinogen Bb 448 polymorphism, fibrinogen levels, and acute coronary disease. Arterioscler Thromb Vasc Biol. 1997;17:589.
106. Nishiuma S, Kario K, Yakushijin K, et al. Genetic variation in the promoter region of the b-fibrinogen gene is associated with ischemic stroke in a Japanese population. Blood Coagul Fibrinolysis. 1998;9:373.
107. Wang XL, Wang J, McCredie RM, Wilcken DEL. Polymorphisms of factor V, factor VII, and fibrinogen genes: relevance to severity of coronary artery disease. Arterioscler Thromb Vasc Biol. 1997;17:246.
108. Baumann RE, Henschen AH. Human fibrinogen polymorphic site analysis by restriction endonuclease digestion and allele-specific polymerase chain reaction amplification: identification of polymorphisms at position Aa312 and Bb448. Blood. 1996;82:2117.
109. Muszbek L, Adany R, Mikkola H. Novel aspects of blood coagulation factor XIII, I: structure, distribution, activation and function. Crit Rev Clin Lab Sci. 1996;33:357.
110. Credo RB. Curtis CG, Lorand L. a-chain domain of fibrinogen controls generation of fibrinoligase (factor XIIIa): calcium ion regulatory aspects. Biochemistry. 1981;20:3770.
111. Curran JM, Evans A, Arveiler D, et al. The a-fibrinogen T/A 312 polymorphism in the ECTIM study. Thromb Haemost. 1998;79:1057.
112. Carter AM, Catto AJ, Grant PJ. Association of the a-fibrinogen Thr 312Ala polymorphism with post stroke mortality in subjects with atrial fibrillation. Circulation. 1999;99:2423.
113. Junker R, Heinrich J, Schlte H, van der Loo J, Assman G. Coagulation factor VII and the risk of coronary heart disease in healthy men. Arterioscler Thomb Vasc Biol. 1997;17:1539.
114. Smith FB, Lee AJ, Fowkes FGR, Price JF, Rumley A, Lowe GDO. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1997;17:3321.
115. Lane A, Green F, Scarabin PY, et al. Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indication of MI risk in the ECTIM study. Atherosclerosis. 1996;119:119.
116. Hoffman CJ, Miller RH, Lawson WE, Hultin MB. Elevation of factor VII activity and mass in young adults at risk of ischemic heart disease. J Am Coll Cardiol. 1989;14:941.
117. Heywood DM, Ossei-Gerning N, Grant PJ. Association of factor VII: C levels with environmental and genetic factors in patients with ischaemic heart disease and coronary atheroma characterised by angiography. Thromb Haemost. 1996;76:161.
118. Vaziri ND, Kennedy SC. Kennedy D, Gonzales E. Coagulation, fibrinolytic, and inhibitory proteins in acute myocardial infarction. Am J Med. 1992;93:651.
119. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood. 1993;81:734.
120. Moor E, Silveira A, van't Hooft F, et al. Coagulation factor VII mass and activity in young men with myocardial infarction at a young age: role of plasma lipoproteins and factor VII genotype. Arterioscler Thromb Vasc Biol. 1995;15:655.
121. Green F, Kelleher C, Wilkes H, Temple A, Meade T, Humphries S. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arteroscler Thromb. 1991;11:540.
122. Marchetti G, Patracchini P, Papaschini M, Ferrati M, Bernardi F. A polymorphism in the 5' region of coagulation factor VII gene (F7) caused by an inserted decanucleotide. Hum Genet. 1993;90: 575.
123. Bernardi F, Marchetti G, Pinotti M, et al. Factor VII gene polymorphisms contribute about one third of the factor VII level variation in plasma. Arterioscler Thromb Vasc Biol. 1996;16:72.
124. Pollak ES, Hung HL, Godin W, Overton GC, High KA. Functional characterization of the human factor VII 5'-flanking region. J Biol Chem. 1996;271:1738.
125. van't Hooft FM, Silveira A, Tomvall P, et al. Two common functional polymorphisms in the promoter region of coagulation factor VII gene determining plasma factor VII activity and mass concentration. Blood. 1999;93:3432.
126. Lane A, Cruikshank JK, Mitchell J, Henderson A, Humphries S. Green FR. Genetic and environmental determinants of factor VII coagulant activity in ethnic groups at different risk of coronary heart disease. Atherosclerosis. 1992;94:43.
127. Hunault M, Arbini AA, Lopaciuk S, Carew JA, Bauer KA. The Arg353Gln polymorphism reduces the level of coagulation factor VII: in vivo and in vitro studies. Arterioscler Thromb Vasc Biol. 1997;17:2825.
128. Humphries SE, Lane A, Green FR, Cooper J, Miller GJ. Factor VII coagulant activity and antigen levels in healthy men are determined by factor VII genotype and plasma triglyceride concentration. Arterioscler Thromb Vasc Biol. 1994;14:193.
129. Hong Y, Pedersen NL, Egberg N, de Faire U. Genetic effects for plasma factor VII levels independent of and in common with triglycerides. Thromb Haemost. 1999;81:382.
130. Mennen LI, de Maat MPM, Schouten EG, et al. Coagulation factor VII, serum-triglycerides and the R/Q353 polymorphism: differences between older men and women. Thromb Haemost. 1997;78:984.
131. Doggen CJM, Cats VM, Bertina RM, Reitsma PH, Vandenbroucke JP, Rosendaal FR. A genetic propensity to high factor VII is not associated with the risk of myocardial infarction in men. Thromb Haemost. 1998;80:281.
132. Iacoviello L, Di Castelnuovo A, de Knijff P, et al. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med. 1998;338:79.
133. Lensen RPM, Rosendaal FR, Koster T, et al Apparent different thrombotic tendency in patients with factor V Leiden and protein C deficiency due to selection of patients. Blood. 1996;88:4205.
134. Heywood DM, Carter AM, Catto AJ, Bamford JM, Grant PJ. Polymorphisms of the factor VII gene and circulating FVIIC levels in relation to acute cerebrovascular disease and post stroke mortality. Stroke. 1997;28:816.
135. Shebuski RJ, Sitko GR, Claremon DA, et al. Inhibition of factor XIIIa in a canine model of coronary thrombosis: effect of reperfusion and acute reocclusion after recombinant tissue-type plasminogen activator. Blood 1990;76:1455.
136. Reed GL, Houng AK. The contribution of activated Factor XIII to fibrinolytic resistance in experimental pulmonary embolus. Circulation. 1999;99:299.
137. Kohler HP, Stickland MH, Ossei-Geming N, Carter A, Mikkola H, Grant PJ. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost. 1998;79:8.
138. Kohler HP, Grant PJ. Clustering of haemostatic risk factors with FXIIIVal34Leu in patients with myocardial infarction [letter]. Thromb Haemost. 1998;80:862.
139. Kohler HP, Mansfield MW, Clark PS, Grant PJ. Interaction between insulin resistance and factor XIIII Val34Leu in patients with coronary heart disease. Thromb Haemost. 1999;82:1202.
140. Konter HP, Futers T, Grant PJ. Prevalence of three common polymorphisms in the a-subunit gene of factor XIII in patients with coronary artery disease: association with FXIII activity and antigen levels. Thromb Haemost. 1999;81:511.
141. Wartiovaara U, Perola M, Mikkola H, et al. Association of FXIII Val34Leu with decreased risk of myocardial infarction in Finnish males. Atherosclerosis. 1999;142:295.
142. McCormack L, Kain K, Catto AJ, Kohler HP, Stickland MH, Grant PJ. Prevalence of FXIII V34L in populations with different cardiovascular risk. Thromb Haemost. 1998;80:523.
143. Catto AJ, Kohler HP, Bannan S, Stickland M, Carter A, Grant PJ. Factor XIIIVal34Leu: a novel association with primary intracerebral haemorrhage. Stroke. 1998;29:813.
144. Emmerich J, Poirier O, Evans A, et al. Myocardial infarction, Arg 506 to Gln factor V mutation, and activated protein C resistance [letter]. Lancet. 1995;345:321.
145. Ardissino D, Peyvandi F, Merlini PA, Colombi E, Mannucci PM. Factor V (Arg506 to Gln) mutation in young survivors of myocardial infarction. Thromb Haemost. 1996;75:701.
146. Cushman M, Rosendaal FR, Psaty BM, et al. Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: results from the Cardiovascular Health Study. Thromb Haemost. 1998;79:912.
147. Catto A, Carter A, Ireland H, et al. Factor V Leiden gene mutation and thrombin generation in relation to acute stroke. Arterioscler Thromb Vasc Biol. 1995;15:783.
148. Longstreth WT, Rosendaal FR, Siscovick DS, et al. Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A). Stroke. 1998;29:577.
149. Rosendaal FR, Siscovick DS, Schwartz SM, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood. 1997;89:2817.
150. Rosendaal FR, Siscovick DS, Schwartz SM, et al. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood. 1997;90:1747.
151. Doggen CJM, Cats VM, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation. 1998;97:1037.
152. Kiechl S, Muigg A, Santer P, et al. Poor response to activated protein C as a prominent risk predictor of advanced arterial disease. Circulation. 1999;99:614.
153. Salomaa V, Matei C, Aleksic N, et al. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study. Lancet. 1999;353:1729.
154. Kunz G, Ireland H, Stubbs PJ, Kahan M, Coulton GC, Lane DA. Identification and characterization of a thrombomodulin gene mutation coding for an elongated protein with reduced expression in a kindred with myocardial infarction. Blood. 2000;95:569.
155. Norland L, Zoller B, Ohlin AK. A novel thrombomodulin gene mutation in a patient suffering from saggital sinus thrombosis. Thromb Haemost. 1997;78:1164.
156. Doggen CJM, Kunz G, Rosendaal FR, et al. A mutation in the thrombomodulin gene, 127G to A coding for Ala25Thr, and the risk of myocardial infarction. Thromb Haemost. 1998;80:743.
157. Norland L, Holm J, Zoller B, Ohlin AK. A common thrombomodulin amino acid dimorphism is associated with myocardial infarction. Thromb Haemost. 1997;77:248.
158. Ireland H, Kunz G, Kyriakoulis K, Stubbs PJ, Lane DA. Thrombomodulin gene mutations associated with myocardial infarction. Circulation. 1997;96:15.
159. Collen D. The plasminogen (fibrinolytic) system. Thromb Haemost. 1999;82:259.
160. Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long term mortality in patients with coronary artery disease. Circulation. 1993;88:2030.
161. Thompson SG, Kienast J, Pyke SDN, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995;332:635.
162. Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and the risk of cardiovascular events. Thromb Haemost. 1997;78:656.
163. Ludwig M, Wihn K-D, Scheuning W-D, Olek K. Alleleic dimorphism in the human tissue-type plasminogen activator (TPA) gene as a result of an Alu insertion/deletion event. Hum Genet. 1992;88:388.
164. van den Eijnden-Schrauwen Y, Lakenberg N, Emeiss JJ, de Knijff P. Alu-repeat polymorphism in the tissue-type plasminogen activator gene does not affect basal endothelial tPA synthesis [letter]. Thromb Haemost. 1995;74:1202.
165. van der Bom JG, de Knijff P, Haverkate F, et al. Tissue plasminogen activator and the risk of myocardial infarction: the Rotterdam Study. Circulation. 1997;95:2623.
166. Ridker PM, Baker MT, Hennekens CH, Stampfer MJ, Vaughan DE. Alu-repeat polymorphism in the gene coding for tissue-type plasminogen activator (t-PA) and risks of myocardial infarction among middle-aged men. Arterioscler Thromb Vasc Biol. 1997;17:1687.
167. lacoviello L, Di Castelnuovo A, De Knijff P, et al. Alu-repeat polymorphism in the t-PA gene, tPA levels and the risk of familial AMI. Fibrinolysis. 1996;10:13.
168. rd ed. Edinburgh: Churchill Livingstone; 1994:699.
169. Lupu F, Bergonzelli GE, Heim DA, et al. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb. 1993;13:1090.
170. Sobel BE, Woodcock-Mitchell J, Schneider DJ, Holt RE, Marutsuka K, Gold H. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with non-diabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation. 1998;97:2213.
171. Margaglione M, Di Minno G, Grandone E, et al. Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke. Arterioscler Thromb. 1994;14:1741.
172. Thogersen AM, Jansson JH, Boman K, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation. 1998;98:2241.
173. Mansfield MW, Stickland MH, Grant PJ. PAI-1 concentrations in first degree relatives of patients with non-insulin-dependent diabetes mellitus: metabolic and genetic associations. Thromb Haemost. 1997;77:357.
174. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasminogen activator inhibitor-1 activity. Arterioscler Thromb. 1991;11:183.
175. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem. 1993;268:10,739.
176. Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries SE, Yudkin J. Determinants of plasminogen activator inhibitor-1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor-1 gene. Diabetes. 1995;44:37.
177. Mansfield MW, Stickland MH, Grant PJ. Plasminogen activator inhibitor-1 promoter polymorphism and coronary artery disease in non-insulin dependent diabetes. Thromb Haemost. 1995;74:1032.
178. Eriksson P, Nilsson L, Karpe F, Hamsten A. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 1998;18:20.
179. Cesari M, Sartori MT, Patrassi GM, Vettore S, Rossi GP. Determinants of plasma levels of plasminogen activator inhibitor-1 : a study of normotensive twins. Arterioscler Thromb Vascl Biol. 1999;19:316.
180. Henry M, Chomiki N, Scarabin PY, et al. Five frequent polymorphisms of the PAI-1 gene: tack of association between genotypes, PAI activity, and triglyceride levels in a healthy population. Arterioscler Thromb Vascl Biol. 1997;17:851.
181. Henry M, Tregouet DA, Alessi MC, et al. Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort. Arterioscler Thromb Vasc Biol. 1998;18:84.
182. Ye S, Green FR, Scarabin PY, et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost. 1995;74:837.
183. Ossei-Gerning N, Mansfield MW, Stickland MH, Wilson U, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and levels in relation to a history of myocardial infarction in patients characterised by coronary angiography. Arterioscler Thromb Vasc Biol. 1997;17:33.
184. Eriksson P, Kallin B, van't Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA. 1995;92:1851.
185. Burzotta F, Di Castelnuovo A, Amore C, et al. 4G/5G promoter PAI-1 gene polymorphism is associated with plasmatic PAI-1 activity in Italians: a model of gene-environment interaction. Thromb Haemost. 1998;79:354.
186. Stegnar M, Uhrin P, Peternel P, et al. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost. 1998;79:975.
187. Margaglione M, Grandone E, Vecchione G, et al. Plasminogen activator inhibitor-1 (PAI-1) antigen plasma levels in subjects attending a metabolic ward: relation to polymorphisms of PAI-1 and angiotensin converting enzyme (ACE) genes. Arterioscler Thromb Vasc Biol. 1997;17:2082.
188. Margaglione M, Cappucci G, Colaizzo D, et al. The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease. Arterioscler Thromb Vasc Biol. 1998;18:152.
189. Iwai N, Shimoike H, Nakamura Y, Tamaki S, Kinoshita M. The 4G/5G polymorphism of the plasminogen activator inhibitor gene is associated with the time course of progression to acute coronary syndromes. Atherosclerosis. 1998;136:109.
190. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Miletich JP. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation. 1997;95:59.
191. Doggen CJM, Bertina RM, Manger Cats V, Reitsma PH, Rosendaal FR. The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with myocardial infarction. Thromb Haemost. 1999;82:115,
192. Gardemann A, Lohre J, Katz N, Tillmanns H, Hehrlein FW, Haberbosch W. The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease. Thromb Haemost. 1999;82:1121.
193. lacoviello L, Burzotta F, Di Castelnuovo A, Zito F, Marchioli R, Donati MB. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: a meta-analysis. Thromb Haemost. 1998;80:1029.
194. Catto AJ, Carter AM, Stickland MH, Bamford JM, Davies JA, Grant PJ. Plasminogen activator inhibitor-1 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease. Thromb Haemost. 1997;77:730.
195. nd ed. Baltimore: Williams & Wilkins: 1998:229.
196. Andrews RK. Shen Y, Gardiner EE, Dong JF, Lopez JA, Berndt MC. The glycoprotein Ib-IX-V complex in platelet adhesion and signaling. Thromb Haemost 1999;82:357.
197. Ruggeri ZM. New insights into the mechanisms of platelet adhesion and aggregation. Semin Hematol. 1994;31:229.
198. Bray PF. Inherited diseases of platelet glyoproteins: considerations for rapid molecular characterisation. Thromb Haemost. 1994;72:492.
199. Moroi M, Jung SM, Okuma M, Shinmyozu K. A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. J Clin Invest. 1989;84:1440.
200. Nieuwenhuis HK, Akkerman JWN, Houdijk WPM, Sixma JJ. Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature. 1985;318:470.
201. Newman PJ. Platelet alloantigens: cardiovascular as well as immunological risk factors. Lancet. 1997;349:370.
202. Weiss EJ, Bray PF, Tayback M, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med. 1996;334:1090.
203. Goldschmidt-Clermont PJ, Shear WS, Shwartzberg J, Varga CF, Bray PF. Clues to the death of an Olympic champion. Lancet. 1996;348:485.
204. Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ, Lindpaintner K. PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke and venous thrombosis. Lancet. 1997;349:385.
205. Herrmann SM, Poirier O, Marques-Vidal P, et tal. The Leu 33/Pro polymorphism (PIA1/PIA2) of the glycoprotein IIIa (GPIIIa) receptor is not related to myocardial infarction in the ECTIM Study. Thomb Haemost. 1997;77:1179.
206. Carter AM, Ossei-Geming N, Wilson IJ, Grant PJ. Association of the platelet PI(A) polymorphism of glycoprotein IIb/IIIa and the fibrinogen Bb448 polymorphism with myocardial infarction and extent of coronary artery disease. Circulation. 1997;96:1424.
207. Samani NJ, Lodwick D. Glycoprotein IIIa polymorphism and risk of myocardial infarction. Cardiovasc Res. 1997;33:693.
208. Marian AJ, Brugada R, Kleiman NS. Platelet glycoprotein IIIa PIA polymorphism and myocardial infarction. N Engl J Med. 1996;334:1071.
209. Durante-Mangoni E, Davies GJ, Ahmed N, Ruggiero G, Tuddenham EG. Coronary thrombosis and the platelet glycoprotein IIIA gene PIA2 polymorphism. Thromb Haemost. 1998;80:218.
210. Carter AM, Ossei-Gerning N, Grant PJ. Platelet glycoprotein IIIa PIA polymorphism in young men with myocardial infarction. Lancet. 1996;348:485.
211. Ardissino D, Mannucci PM, Merlini PA, et al. Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood. 1999;94:46.
212. Gardemann A, Humme J, Stricker J, et al. Association of the platelet glycoprotein IIIa PIA1/A2 gene polymorphism to coronary artery disease but not to nonfatal myocardial infarction in low risk patients. Thromb Haemost. 1998;80:214.
213. Mamotte CD, van Bockxmeer FM, Taylor RR. PIA1/A2 polymorphism of glycoprotein IIIa and risk of coronary artery disease and restenosis following coronary angioplasty. Am J Cardiol. 1998;82:13.
214. Zotz RB, Winkelmann BR, Nauck M, et al. Polymorphism of platelet membrane glycoprotein IIIa: human platelet antigen Ib (HPA-Ib/PIA2) is an inherited risk factor for premature myocardial infarction in coronary artery disease. Thromb Haemost. 1998;79:731.
215. Walter DH, Schachinger V, Elsner M, Dimmeler S, Zeiher AM. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet. 1997;350:1217.
216. Carter AM, Catto AJ, Bamford JM, Grant PJ. Platelet GpIIIa PIA and GpIb variable number tandem repeat polymorphisms and markers of platelet activation in acute stroke. Arterioscler Thromb Vasc Biol. 1998;18:1124.
217. Carlsson LE, Greinacher A, Spitzer C. Walther R, Kessler C. Polymorphisms of the human platelet antigens HPA-1, HPA-2, HPA-3 and HPA-5 on the platelet receptors for fibrinogen(GPIIb/IIIa), von Willebrand factor (GPIb/IX) and collagen (GPIa/ IIa) are not correlated with an increased risk for stroke. Stroke. 1997;28:1392.
218. Gonzalez-Conejero R, Lozano ML, Rivera J, et al. Polymorphisms of platelet membrane glycoprotein Iba associated with arterial thrombotic disease. Blood. 1998;92:2771.
219. Kunicki TJ, Orchekowski R, Annis D, Honda Y Variability of integrin a2 b1 activity on human platelets. Blood. 1993;82:2693.
220. Di Paola J, Federici AB, Mannucci PM, et al. Low platelet a2ab1 levels in type I von Willebrand disease correlate with impaired platelet function in a high shear stress system. Blood. 1999;93:3578.
221. Santoso S, Kunicki TJ, Kroll H, Haberbosch W, Gardemann A. Association of the platelet glycoprotein Ia C807T gene polymorphism with nonfatal myocardial infarction in younger patients. Blood. 1999;93:2449.
222. Croft SA, Hampton KK, Sorrell JA, et al. The GpIa C807T dimorphism associated with platelet collagen receptor density is not a risk factor for myocardial infarction. Br J Haematol. 1999;106:771.
223. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995;74:1049.
224. Graham IM, Daly LE Refsum HM, et al. Plasma homocystine as a risk factor for vascular disease: the European Concerted Action Project. JAMA. 1997;277:1775.
225. Brattstrom L. Common mutation in the methylenetetrahydrofolate reductase gene offers no support for mild hyperhomocysteinaemia being a causal risk factor for cardiovascular disease. Circulation. 1997;96:3805.
226. Tracy RP. Epidemiological evidence for inflammation in cardiovascular disease. Thromb Haemost. 1999;82:826.